Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

KRON
Kronos Bio, Inc. Common Stock
stock NASDAQ

At Close
May 8, 2025 3:59:30 PM EDT
0.7241USD+0.542%(+0.0039)301,803
0.00Bid   0.00Ask   0.0000Spread
Pre-market
May 7, 2025 8:00:30 AM EDT
0.7104USD-1.361%(-0.0098)0
After-hours
May 7, 2025 4:34:30 PM EDT
0.7111USD-1.291%(-0.0093)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 17, 2021
08:00AM EST  Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in   PR Newswire
Dec 6, 2021
07:11AM EST  Kronos Bio Announces First Patient Dosed In AGILITY Phase 3 Clinical Trial Of Entospletinib In Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia   Benzinga
07:00AM EST  Data in the second half of 2023 could potentially lead to accelerated approvalIf approved, entospletinib would be the first treatment for newly diagnosed patients with the NPM1 mutation who are fit for intensive induction   GlobeNewswire Inc
Nov 29, 2021
07:03AM EST  Kronos Bio Announces Data From Ongoing Phase 1/2 Trial Of Oral CDK9 Inhibitor KB-0742; Co. reports 'Initial data demonstrate long plasma half-life and dose-dependent target inhibition'   Benzinga
07:00AM EST  Initial data demonstrate long plasma half-life and dose-dependent target inhibition   GlobeNewswire Inc
Nov 24, 2021
07:00AM EST  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:   GlobeNewswire Inc
Nov 11, 2021
04:06PM EST  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Roshawn Blunt to the companys Board of Directors.   GlobeNewswire Inc
Nov 10, 2021
06:47AM EST  HC Wainwright & Co. Maintains Buy on Kronos Bio, Raises Price Target to $36   Benzinga
Nov 9, 2021
06:19PM EST  Kronos Bio Q3 EPS $(0.61) Up From $(6.48) YoY   Benzinga
11:14AM EST  Kronos Bio Reports Multi-Year Collab With Tempus To Provide Co. With Access To Tempus Platform, No Terms Disclosed   Benzinga
Nov 4, 2021
07:00AM EDT  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Charles Lin, Ph.D., Senior Vice President, Biology, will participate in the Emerging Trends and Therapeutics in Oncology panel at the BMO Biopharma Spotlight Series on Monday, November 8 at 3:25 p.m. Eastern Time.   GlobeNewswire Inc
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Sep 30, 2021
04:37PM EDT  Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021   Benzinga
04:36PM EDT  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present preclinical data in a poster at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. The meeting will be held from Oct. 7-10, 2021.   GlobeNewswire Inc
Sep 14, 2021
08:00AM EDT  Kronos Bio Appoints Marni Kottle as Senior Vice President of   GlobeNewswire Inc
Sep 7, 2021
07:00AM EDT  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13th at 7 a.m. ET.   GlobeNewswire Inc
Aug 31, 2021
11:23AM EDT  Kronos Bio Sponsored Study Titled 'A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)' Posted To ClinicalTrials.gov; Study Not Yet Recruiting   Benzinga
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 12, 2021
04:32PM EDT  Kronos Bio Q2 EPS $(0.53)   Benzinga
04:05PM EDT  Announced FDA clearance of Investigational New Drug application (IND) for lanraplenib (LANRA) for treatment of patients with acute myeloid leukemia (AML)   GlobeNewswire Inc
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Jul 27, 2021
11:13AM EDT  Kronos Bio Reports FDA Clearance Of Its Investigational New Drug Application For Lanraplenib For Treatment Of Patients With Acute Myeloid Leukemia   Benzinga
Jun 24, 2021
10:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2021   Benzinga
06:11AM EDT  HC Wainwright & Co. Initiates Coverage On Kronos Bio with Buy Rating, Announces Price Target of $35   Benzinga
May 26, 2021
08:00AM EDT  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:   GlobeNewswire Inc
May 25, 2021
08:00AM EDT  Unveils development strategy for lanraplenib (LANRA), which will expand addressable patient population for SYK inhibitor portfolio in acute myeloid leukemia (AML); plans to initiate two Phase 1/2 trials in late 2021 and early 2022   GlobeNewswire Inc
May 11, 2021
04:24PM EDT  Kronos Bio Q1 EPS $(0.48) Up From $(1.23) YoY   Benzinga
04:05PM EDT  Virtual R&D Day on May 25 to unveil SYK portfolio development strategy and highlight momentum of CDK9 inhibitor program and differentiated drug discovery platform   GlobeNewswire Inc
May 6, 2021
08:00AM EDT  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in a fireside chat at the Bank of America Securities 2021 Health Care Conference on Thursday, May 13, 2021 at 1:15 p.m. ET.   GlobeNewswire Inc
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 20, 2021
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
Apr 16, 2021
08:01AM EDT  The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs   Benzinga
Apr 15, 2021
07:49AM EDT  The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split   Benzinga
Apr 14, 2021
07:51AM EDT  The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead   Benzinga
Apr 13, 2021
08:16AM EDT  The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug   Benzinga
Apr 12, 2021
10:23AM EDT  Kronos Bio Saturday Morning Announced Preclinical Data For Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition Of Tumor Growth In Multiple Cancers At American Association For Cancer Research Conference   Benzinga
Apr 10, 2021
08:30AM EDT  MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition   GlobeNewswire Inc
Mar 31, 2021
11:25AM EDT  Kronos Bio, Inc. (Nasdaq: KRON) today commented on the passing of John C. Martin, Ph.D., board member and early investor in the company.   GlobeNewswire Inc
Mar 26, 2021
08:00AM EDT  Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors   GlobeNewswire Inc
Mar 23, 2021
04:07PM EDT  Kronos Bio Q4 EPS $(0.70) Up From $(0.99) YoY   Benzinga
04:05PM EDT  Positive End-of-Phase 2 meeting with the FDA for entospletinib in newly diagnosed NPM1-mutated acute myeloid leukemia   GlobeNewswire Inc
Mar 10, 2021
04:36PM EST  Kronos Bio To Present Pre-Clinical Data At American Association For Cancer Research 2021 For KB-0742, An Oral CDK9 Inhibitor Targeting MYC-Amplified Cancers   Benzinga
04:35PM EST  Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual   GlobeNewswire Inc
Mar 4, 2021
08:12AM EST  The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company   Benzinga
07:03AM EST  Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia   Benzinga
07:00AM EST  Registrational Phase 3 trial will assess measurable residual disease (MRD) negative complete response (CR) as the primary endpoint to support potential accelerated approval   GlobeNewswire Inc
Feb 25, 2021
08:28AM EST  Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers   Benzinga
08:00AM EST  KB-0742 generated using the companys proprietary small molecule microarray (SMM) screening platform   GlobeNewswire Inc
Feb 22, 2021
08:00AM EST  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the Cowen 41st Annual Health Care Conference, a virtual event taking place March 1-4, 2021.   GlobeNewswire Inc
Jan 26, 2021
08:00AM EST  Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors   GlobeNewswire Inc
Dec 8, 2020
08:18AM EST  Kronos Bio Names Pasit Phiasivongsa SVP, Pharmaceutical Development   RTTNews
08:00AM EST  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Pasit Phiasivongsa, Ph.D., as senior vice president, pharmaceutical development. Dr. Phiasivongsa brings more than 20 years of experience in the biopharmaceutical industry overseeing manufacturing processes for novel medicines.   GlobeNewswire Inc
Dec 7, 2020
08:03AM EST  Kronos Bio Announces FDA Clearance Of Investigational New Drug Application For KB-0742, An Oral CDK9 Inhibitor Targeting MYC-amplified Cancers   Benzinga
08:00AM EST  Kronos Bio Announces FDA Clearance of Investigational New Drug   GlobeNewswire Inc
Nov 25, 2020
07:35AM EST  The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback   Benzinga
Nov 24, 2020
08:13AM EST  The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia   Benzinga
Nov 23, 2020
08:00AM EST  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in the following investor conferences:   GlobeNewswire Inc
Nov 18, 2020
08:07AM EST  Kronos Bio Q3 EPS $(6.48), Down From $(0.74) YoY   Benzinga
08:00AM EST  Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of NPM1-mutated acute myeloid leukemia   GlobeNewswire Inc
Nov 11, 2020
08:00AM EST  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Wednesday, Nov. 18, 2020, at 7:20 p.m. GMT (2:20 p.m. ET).   GlobeNewswire Inc
Nov 3, 2020
09:33AM EST  Benzinga's Top Upgrades, Downgrades For November 3, 2020   Benzinga
07:22AM EST  Cowen & Co. Initiates Coverage On Kronos Bio with Outperform Rating   Benzinga
06:22AM EST  Goldman Sachs Initiates Coverage On Kronos Bio with Buy Rating, Announces Price Target of $45   Benzinga
04:44AM EST  Piper Sandler Initiates Coverage On Kronos Bio with Overweight Rating, Announces Price Target of $50   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 22, 2020
08:12AM EDT  Kronos Bio Announces Publication Of Preclinical Study Results For Investigational CDK9 Inhibitor KB-0742 In Cell Chomical Biology   Benzinga
08:00AM EDT  KB-0742 is a transcription regulatory network modulator discovered using the companys proprietary high-throughput screening platform   GlobeNewswire Inc
Oct 18, 2020
05:10PM EDT  Last Week's Notable Insider Buys: Carnival, Citigroup And More   Benzinga
Oct 14, 2020
04:05PM EDT  Kronos Bio Announces Closing of Initial Public Offering and Full   GlobeNewswire Inc
Oct 10, 2020
03:09AM EDT  Mid-Afternoon Market Update: Nasdaq Rises 1.2%; VivoPower International Shares Spike Higher   Benzinga
Oct 9, 2020
12:02PM EDT  Kronos Bio Shares Open For Trade At $28.50; IPO Priced At $19/Share   Benzinga
10:03AM EDT  FuboTV Uplisting, Kronos Bio Highlight This Week's IPOs   Benzinga
09:11AM EDT  IPOs Happening Today, Friday, October 9, 2020: LCYAU, STTK, SPRB, IH, KRON, IPOD.U, IPOE.U, IPOF.U   Benzinga
08:52AM EDT  Kronos Bio Shares Expected To Open For Trade Today, IPO Priced At $19.00/Share   Benzinga
Oct 8, 2020
08:54PM EDT  Kronos Bio Prices IPO Of 13.16 Mln Shares At $19.00/shr   RTTNews
08:00PM EDT  Kronos Bio Announces Pricing of Initial Public Offering   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC